regulation
AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
AbbVie has applied for European Union authorisation of a subcutaneous formulation of Skyrizi in Crohn's disease.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Fri · 28 Aug
regulation
AbbVie has applied for European Union authorisation of a subcutaneous formulation of Skyrizi in Crohn's disease.
Markets open original ↗
product
CRISPR Therapeutics presented Phase 1a data for CTX310, its in vivo ANGPTL3 gene-editing candidate, at ESC Congress 2026. The company describes deep and durable ANGPTL3 editing with triglyceride and LDL lowering. Specific percentage reductions are in the release but are not restated here.
Markets open original ↗
regulation
The FDA approved a once-daily HIV pill from Gilead Sciences intended to simplify treatment for some patients, per CNBC. No trial or pricing figures are reproduced here beyond what the headline states.
Markets open original ↗
partnership
The U.S. Air Force awarded Boeing the sole-source "F-15 Eagle Crest" indefinite-delivery/indefinite-quantity contract on 24 August, capping at $131.23 billion what it may order through 2031 (extendable to 2036) for F-15 production, systems integration, modernization, retrofits, sustainment and organic depot maintenance, for the Air Force, Air National Guard and foreign buyers. The ceiling is not a commitment: only $343,740 in fiscal 2026 RDT&E funds was obligated at award.
Markets open original ↗
partnership
Teva announced a proposed acquisition of a novel neuroscience product under its Pivot to Growth strategy. A same-day release from BioXcel Therapeutics announcing an asset sale agreement with Teva Pharmaceuticals identifies the counterparty. Deal terms are not stated in the headline and are not reproduced here.
Markets open original ↗